Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Dec 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called diltiazem to treat a heart condition known as atrial fibrillation or atrial flutter, which can cause a rapid heart rate. The goal of the trial is to see if giving a calcium supplement before administering diltiazem can help reduce the chances of a side effect called hypotension, or low blood pressure, that may occur after taking the medication.

To participate in this trial, you need to be at least 18 years old and have a diagnosis of atrial fibrillation or flutter with a rapid heart rate of 120 beats per minute or more. However, people who are pregnant, have certain heart conditions, or have specific allergies to the medications used in the trial cannot participate. If you join the trial, you will be monitored closely to see how well the treatment works and if it helps in reducing the risk of low blood pressure. This study is currently recruiting participants, and your involvement could contribute to important findings in heart care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years or older
• • Able to provide informed consent
• • Primary diagnosis AFF with RVR greater than or equal to 120 bpm
• Exclusion Criteria:
• • Pregnancy defined as a positive urine HCG
• • Hemodynamically unstable patients (SBP \<90, MAP \<65)
• • Stated history of systolic heart failure with reduced ejection fraction (\<40%) or evidence of acute heart failure or reduced EF (peripheral edema, JVD, pulmonary edema) on clinical exam or bedside echo
• • Patients with left ventricular assist device
• • Sinus node dysfunction or preexcitation with accessory pathway (known diagnosis of SVT, WPW or sick sinus syndrome. Delta waves or other evidence of accessory pathway on EKG)
• • 2nd or 3rd degree atrioventricular block
• • Allergy or sensitivity to any study drugs
• • Previously enrolled in this trial during a different patient encounter
• • Non-English speaking